RecruitingNCT06675643

Digital Remote Monitoring of Immune Checkpoint Inhibitor Therapy Induced Toxicity Using the Vigilant App

Digital Remote Monitoring of Immune Checkpoint Inhibitor Therapy Induced Toxicity: A Feasibility Study of the Vigilant App (Vigilant-2)

Sponsor

Mayo Clinic

Enrollment

100 participants

Start Date

Oct 14, 2024

Study Type

OBSERVATIONAL

Conditions

Melanoma Malignant Skin Neoplasm

Summary

This study is being done to better understand patient experiences with using a mobile application, known as Vigilant, to monitor symptoms as outpatients and to gather preliminary data on the potential clinical benefit to remote monitoring of adverse events.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a smartphone app called Vigilant that remotely monitors patients receiving dual immunotherapy (ipilimumab and nivolumab) for skin cancer or melanoma. The goal is to detect side effects earlier so they can be managed before they become serious. **You may be eligible if...** - You have skin cancer or melanoma and are starting treatment with the combination of ipilimumab and nivolumab (dual immune checkpoint inhibitor therapy) **You may NOT be eligible if...** - You do not meet the above inclusion criteria Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.